Tricida Announces Closing of Offering of $200 Million of 3.50% Convertible Senior Notes Due 2027, Including Full Exercise of Option to Purchase Additional Notes

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tricida, Inc. (Nasdaq: TCDA) , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the closing of its previously announced offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2027 (the “Notes”), which includes the exercise in full by the initial purchasers of their option to purchase an additional $25.0 million aggregate principal amount of Notes, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).